Pharma in silica inaugurates its new high-safety laboratory

Quebec City, July 27, 2020 – Big day for Pharma in silica: their own laboratory is inaugurated.

The preclinical-stage company develops a safe treatment for solid tumors, associating silica-based nanoparticles with potent cancer drugs such as paclitaxel. The endeavor calls for three demanding sets of attributes: a) compatibility with a unusual manufacturing technology, b) robust personal and environmental safety and c) strict quality control for the product itself. This set of attributes is not part of the service offering of your typical CRO or university lab (we checked).

The 45 m² laboratory and its dedicated equipment satisfy the company's needs in product development and small-lot production up to the conclusion of phase III clinical trials. « We have reached a significant milestone », said François Arcand, the president of Pharma in silica. « Its great to be home and see the major productivity gains ahead of us ».

SiliCycle, Pharma in silica's sister company, designed and built the state-of-the-art facility within its most recent extension, with convenient access to the regular chemistry laboratories and the numerous analytical tools it maintains. « With this lab, Pharma in silica enhances consolidates its translational capacity toward animal and human assays », declared professor Nicolas Bertrand, a nanomedicine specialist.

About Pharma in silica inc.

Laboratoires Pharma in silica inc. is a preclinical-stage pharmaceutical company based in Québec City's Parc Technologique. Since 2019, it has been developing novel treatments for solid cancers (lung, breast, etc.) using OpPacli™, a patented drug nanocarrier. The company is driven by a dynamic group of chemists, pharmacists and managers led by François Arcand, an experienced life sciences entrepreneur (Medicago, Conferences on Plant-made Pharmaceuticals, ERA Biotech). The company established its own research and production facilities and collaborates with oncology experts and world-renowned research centers and has completed the pre-IND/CTA meetings with the FDA and Health Canada.

For more information

François Arcand
President, Pharma in silica inc
514 994 1023 / 418 874-0054 #233
info@pharma-insilica.com

> all news